Company Profile
Assembly Biosciences Stock Price, News & Analysis
- Ticker:
- ASMB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
26.45 USD (-0.32%)
Close
Last updated: August 6, 2026
485M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ASMB closed down 0.32% at $26.45. No new same-company headline was identified in the current news window.
Company overview
Antiviral Small Molecules
Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment.
Recurrent Genital Herpes
ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes. These programs are partnered with Gilead for subsequent development planning.
Hepatitis Delta Program
ABI-6250 is an oral small-molecule entry inhibitor for chronic hepatitis delta virus infection and has completed chronic toxicology studies supporting Phase 2 development.
Future catalysts
Initiation of a Phase 2 study of ABI-6250 in chronic hepatitis delta virus infection in the fourth quarter of 2026.
Recent news
- 01
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Source: Assembly Biosciences
- 02
- 03
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Source: Assembly Biosciences
- 04
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Source: Assembly Biosciences
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Assembly Biosciences (ASMB)?
Assembly Biosciences (ASMB) most recently closed at 26.45 USD, a -0.32% move versus the previous session.
What is the market cap of Assembly Biosciences (ASMB)?
Assembly Biosciences currently has a market capitalization of 485M USD on BioPharmSignal.
What does Assembly Biosciences do?
Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in...
On which exchange is ASMB stock listed?
Assembly Biosciences (ASMB) is associated with NASDAQ, United States, Biopharma.
What is ABI-5366?
Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes.
Which conditions is Assembly Biosciences targeting with ABI-5366?
Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in...
How does Assembly Biosciences describe recent progress with ABI-5366?
Initiation of a Phase 2 study of ABI-6250 in chronic hepatitis delta virus infection in the fourth quarter of 2026.
What is ABI-1179?
Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes.